Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06ZAY
|
|||
| Former ID |
DAP001332
|
|||
| Drug Name |
Haloprogin
|
|||
| Synonyms |
Aloprogen; Haloprogina; Haloprogine; Haloproginum; Halotex; Mycanden; Mycilan; Polik; Component of Halotex; M 1028; Haloprogina [INN-Spanish]; Haloprogine [INN-French]; Haloproginum [INN-Latin]; Halotex (TN); Mycanden (TN); Mycilan (TN); Polik (TN); Haloprogin [USAN:INN:JAN]; M-1028 (Meiji); Haloprogin (JAN/USAN/INN); Ether, 3-iodo-2-propynyl 2,4,5-trichlorophenyl; Benzene,1,2,4-trichloro-5-[(3-iodo-2-propynyl)oxy]; (3-Iod-2-propinyl)-(2,4,5-trichlorphenyl)ether; 1,2,4-trichloro-5-(3-iodoprop-2-ynoxy)benzene; 1,2,4-trichloro-5-[(3-iodo-2-propynyl) oxy]benzene; 2,4,5-Trichlorophenyl .gamma.-iodopropargil ether; 2,4,5-Trichlorophenyl .gamma.-iodopropargyl ether; 2,4,5-Trichlorophenyl gamma-iodopropargil ether; 2,4,5-Trichlorophenyl iodopropargyl ether; 2,4,5-Trichlorophenyl-gamma-iodopropargyl ether; 3-Iodo-2-propynyl 2,4,5-trichlorophenyl ether
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Candidiasis [ICD-11: 1F23] | Approved | [1], [2] | |
| Dermatophytosis [ICD-11: 1F28.2; ICD-10: B35.3] | Approved | [1], [2] | ||
| Therapeutic Class |
Antifungal Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H4Cl3IO
|
|||
| Canonical SMILES |
C1=C(C(=CC(=C1Cl)Cl)Cl)OCC#CI
|
|||
| InChI |
1S/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2
|
|||
| InChIKey |
CTETYYAZBPJBHE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 777-11-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
403590, 640756, 5123762, 7847405, 8149366, 8152251, 10321332, 11335937, 11361176, 11364777, 11367339, 11369901, 11378067, 11462148, 11495666, 14953597, 29222692, 46504892, 48334522, 49968903, 50125846, 50761236, 57321871, 99301850, 103399575, 104076881, 104303875, 117456103, 124766487, 125664306, 126690183, 134338547, 134978565, 136196453, 137006430, 139837001, 144206294, 160964135, 175611838, 177749232, 179116719, 198949670, 223681392, 225144320, 226395785, 241133416, 250046776, 252559360
|
|||
| ChEBI ID |
CHEBI:5614
|
|||
| SuperDrug ATC ID |
D01AE11
|
|||
| SuperDrug CAS ID |
cas=000777117
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides uniformis was decreased by Haloprogin (adjusted p-values: 4.26E-04). | |||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Haloprogin (adjusted p-values: 2.18E-03). | |||
|
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Prevotella copri was decreased by Haloprogin (adjusted p-values: 3.97E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Enterocloster bolteae
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Enterocloster bolteae was decreased by Haloprogin (adjusted p-values: 5.74E-03). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fungal Cell membrane (Fung CM) | Target Info | Binder | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Drug information of Haloprogin, 2008. eduDrugs. | |||
| REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 4 | Haloprogin: mode of action studies in Candida albicans. Can J Microbiol. 1974 Sep;20(9):1241-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.